Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

11.8%

2 terminated/withdrawn out of 17 trials

Success Rate

86.7%

+0.2% vs industry average

Late-Stage Pipeline

35%

6 trials in Phase 3/4

Results Transparency

46%

6 of 13 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 2
8(47.1%)
Phase 3
5(29.4%)
Phase 1
3(17.6%)
Phase 4
1(5.9%)
17Total
Phase 2(8)
Phase 3(5)
Phase 1(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials
NCT00816673Phase 2Completed

Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs

Role: lead

NCT02615002Phase 2Completed

Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

Role: lead

NCT05267535Phase 2Active Not Recruiting

Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

Role: lead

NCT01906866Phase 3Completed

Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities

Role: lead

NCT04233502Phase 3Withdrawn

Efficacy and Safety of Slenyto for Insomnia in Children With ASD

Role: lead

NCT01489969Phase 2Completed

Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients

Role: lead

NCT00940589Phase 2Completed

Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor

Role: lead

NCT00397189Phase 3Completed

Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients

Role: lead

NCT00607451Phase 1Terminated

Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia

Role: lead

NCT01903681Phase 1Completed

Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances

Role: lead

NCT02087722Phase 3Completed

Efficacy and Safety of KI1001 in the Treatment of ≥ 55 Years Old Insomnia Patients

Role: collaborator

NCT01450228Phase 3Completed

Efficacy and Safety of KI1001 in ≥ 55 Years Old Insomnia Patients

Role: collaborator

NCT01280734Phase 4Completed

Investigation of Melatonin and Zolpidem Effect on Postural Instability in Healthy Adult Subjects

Role: lead

NCT01114126Phase 1Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Neu-P11 in Subjects With Primary Insomnia

Role: lead

NCT00972075Phase 2Completed

Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects

Role: lead

NCT00869128Phase 2Completed

A Study of the Efficacy of Prolonged-Release Melatonin Versus Placebo in Diabetic Patients Suffering From Insomnia

Role: lead

NCT00544791Phase 2Unknown

The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment

Role: collaborator

All 17 trials loaded